Search Results

, such as gemtuzumab ozogamicin (GO) added to induction and consolidation therapy for those with CBF leukemias, liposomal formulations for older patients with secondary leukemias, and the addition of midostaurin for those with FLT3 mutations. “It is

synergistically with ATRA. 13 , 14 The addition of ATO as first-line consolidation therapy with ATRA and anthracycline (following standard induction with ATRA, anthracycline, and cytarabine) resulted in improved outcomes in the North American Intergroup trial. 9

for patients with MAC, the SABR-COMET trial by Palma et al 8 and the study of local consolidative therapy in oligometastatic non–small cell lung cancer by Gomez et al 9 have shown a positive role for aggressive local therapy, including stereotactic

OS Evaluate the ability of the induction and consolidation therapy to get 70% of patients to ASCT Evaluate the tolerability and CD34+ cell yield after therapy with patient and hyperfractionated cyclophosphamide, doxorubicin, vincristine, and

measured at baseline and at the end of first ofatumumab infusion with ORR, CRR, MRD, TTP, PFS, and OS Evaluate the ability of the induction and consolidation therapy to get 70% of patients to ASCT Evaluate the tolerability and CD34+ cell yield

/refractory tumor specimens Correlate serum C3, C4, and CH50 levels measured at baseline and at the end of first ofatumumab infusion with ORR, CRR, MRD, TTP, PFS, and OS Evaluate the ability of the induction and consolidation therapy to obtain 70% of patients to

ASCT followed by maintenance, single ASCT followed by both PI- and IMiD-containing consolidation therapy and then maintenance, or tandem ASCT followed by maintenance, has just completed accrual and will likely clarify the feasibility and role of tandem

, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia . The International Acute Myeloid Leukemia Study Group . Blood 1997 ; 90 : 4710 – 4718

of Texas MD Anderson Cancer Center: Randomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR) Pasi A. Jänne, MD, PhD, Dana-Farber/Brigham and Women's Cancer

consolidation therapy with cytarabine, 0.75 g/m 2 /d for 3 days; idarubicin, 8 mg/m 2 /d for 2 days; and sorafenib, 400 mg twice daily for 28 days. 8 This was complicated by prolonged myelosuppression, sepsis, clostridium difficile infection, weakness, and